MorphoSys AG

General information
MorphoSys AG
Semmelweisstr. 7
82152 Planegg, Bavaria
Germany

Contact person: Julia Neugebauer, Senior Director Investor Relations
Company main phone: +49 (89) 899270
Company main fax:  +49 (89) 89927222
Website:  https://www.morphosys.com
Year founded:1992
Source of foundation:Independent foundation
No. of employees: Worldwide:  629
Corporate description / mission:
At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter and LinkedIn.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 1999
Remarks on ownership / listings
MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Antibodies
  • Immunotherapy
  • Small molecules
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Neoplasms / cancer / oncology
Business model:
  • Manufacturer
  • Out-licensing
  • R&D
  • Supplier / Distributor
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
  • Small biotech
Distribution:
  • Direct (own sales force)
Summary Products / Services / Technologies
Description of products:
Tafasitamab
Pelabresib
CPI-0209, etc.
Special IP situation:
MorphoSys has built a strong IP portfolio around its proprietary technology, HuCAL.
Technology used:
HuCAL (Human Combinatorial Antibody Library) technology
Financing details
Fiscal year (end of) 2022
Revenues:EUR 278.27M
R&D expenses:EUR 297.81M
No. of shares:34'166'000
Market cap. / valuation:EUR 489.77M
Collaborations & Clients
Partnering strategy / collaborations:
Novartis
I-Mab
GSK
pfizer
Ultragenyx and Mereo Biopharma etc
© 2023 Biotechgate by Venture Valuation
X